AUCTORES
Globalize your Research

Journal of General Medicine and Clinical Practice

Emmanuel Ifeanyi Obeagu *

Open Access

Review Article

Hematologic and Immunologic Crossroads: HIV in Sickle Cell Disease Patients

Emmanuel Ifeanyi Obeagu

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

***Corresponding Author:** Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

Received date: March11, 2025; Accepted date: March 27, 2025; Published date: April 08, 2025

Citation: Emmanuel I. Obeagu (2025), Hematologic and Immunologic Crossroads: HIV in Sickle Cell Disease Patients, *J. General Medicine and Clinical Practice*, 8(4); **DOI:10.31579/2639-4162/261**

Abstract

The coexistence of HIV and sickle cell disease (SCD) presents unique clinical challenges, as both conditions significantly impact hematologic and immunologic systems. HIV, by causing immune suppression, exacerbates the complications of SCD, including increased frequency and severity of vaso-occlusive crises, infections, and organ damage. The pathophysiological interplay between these two diseases complicates diagnosis, treatment, and overall management. This review explores the hematologic and immunologic crossroads that occur in HIV-positive SCD patients, discussing how each disease influences the progression and clinical manifestations of the other. The immunosuppressive effects of HIV compound the already heightened inflammatory state present in SCD, leading to a greater risk of infections, organ failure, and accelerated progression of SCD-related complications. The chronic inflammation and endothelial dysfunction caused by SCD, coupled with the immune dysfunction associated with HIV, exacerbate the severity of both conditions. Additionally, certain medications used in the treatment of HIV, such as antiretroviral therapy (ART), can interact with SCD treatments like hydroxyurea, leading to compounded hematologic challenges. This necessitates careful consideration of therapeutic regimens to minimize adverse interactions and optimize patient care.

Kew Words: hiv; sickle cell disease; hematologic complications; immunologic responses; co-*infection*

Introduction

The intersection of HIV and sickle cell disease (SCD) in affected individuals presents a significant clinical challenge due to the complex interplay between the two conditions. Both HIV and SCD are chronic diseases that, when present together, increase the risk of severe complications, including enhanced inflammatory responses, infections, and organ damage. Understanding the combined pathophysiology of HIV and SCD is crucial for improving clinical management and patient outcomes. The need for integrated care approaches that address the unique challenges faced by co-infected patients is paramount, as managing each condition individually may not be sufficient to provide optimal care. [1-2]. Sickle cell disease is an inherited hemoglobinopathy characterized by the presence of abnormal hemoglobin (HbS), which leads to the deformation of red blood cells into sickle-shaped forms under low oxygen conditions. This deformity disrupts normal blood flow, causing vaso-occlusive crises, hemolysis, and end-organ damage. The chronic inflammation associated with SCD also predisposes patients to infections, particularly due to the damage to the spleen and impaired immune responses. HIV, a viral infection that leads to progressive immune suppression by targeting CD4+ T cells, further complicates the immune landscape in individuals with SCD. The combination of these two diseases results in compounded hematologic and immunologic dysfunction, creating a distinct pathophysiological profile. [3-5]. HIV's effects on the immune system can exacerbate the already compromised immune function in individuals with SCD. The immune suppression caused by HIV infection makes SCD patients more susceptible to opportunistic infections, which can worsen their clinical course. Moreover, HIV can accelerate the progression of SCD-related complications, such as organ damage, vasculopathy, and chronic pain. Conversely, the chronic inflammation and oxidative stress seen in SCD contribute to the exacerbation of HIV infection, impairing the body's ability to control viral replication effectively. This reciprocal impact underscores the need for a comprehensive approach to managing both diseases simultaneously.[6]

In addition to the immune-related challenges, there are significant hematologic considerations when managing co-infected patients. Antiretroviral therapy (ART), which is the cornerstone of HIV treatment, can have hematologic side effects, including bone marrow suppression, anemia, and neutropenia. This complicates the management of SCD, where maintaining adequate red blood cell levels and managing sickle cell-related crises are critical. Furthermore, some ART drugs may interact with medications commonly used to treat SCD, such as hydroxyurea, leading to adverse effects or reduced efficacy. Thus, finding the right balance in the therapeutic regimen requires careful monitoring and adjustment based on each patient's unique needs. [7-9]. Patients with both HIV and SCD face significant clinical challenges when it comes to the prevention and treatment of infections. SCD patients already have a heightened risk of infection due to impaired immune responses and organ damage, particularly from splenic dysfunction. HIV infection further weakens the immune system, making it

more difficult for these patients to fight infections. This increased vulnerability to infections, including pneumonia, urinary tract infections, and fungal infections, requires careful management to prevent life-threatening complications. Vaccination, prophylactic antibiotics, and early intervention with antimicrobial agents become even more essential in these individuals. [10-12]. Given the complexity of managing both HIV and SCD, a multi-disciplinary approach is essential. This involves collaboration between hematologists, infectious disease specialists, immunologists, and other healthcare professionals to develop personalized treatment plans. Coordination of care is key to managing the myriad complications that can arise in co-infected individuals, including pain crises, anemia, organ failure, and the adverse effects of drug interactions. The goal of treatment is not only to manage HIV viral load but also to reduce the frequency and severity of SCD-related crises, improve quality of life, and prevent long-term complications. [13-14].

Pathophysiology of HIV in Sickle Cell Disease

The pathophysiology of HIV in sickle cell disease (SCD) involves a complex interplay between the immunologic and hematologic dysfunctions inherent to each condition, exacerbating the overall clinical picture. Both HIV and SCD lead to chronic inflammation and immune dysregulation, but their mechanisms of action differ, compounding the severity of symptoms when they co-occur. In SCD, the abnormal sickling of red blood cells induces vaso-occlusive episodes, hemolysis, and endothelial dysfunction, which triggers an inflammatory cascade. The immunological effects of HIV, particularly CD4+ T-cell depletion, lead to progressive immunosuppression, creating an environment where infections and disease progression are more difficult to manage. The presence of HIV in patients with SCD significantly increases the risk of infections, further complicating the clinical course and accelerating organ damage.[15-17]. In individuals with SCD, the chronic inflammatory state results from the repeated episodes of hemolysis and vaso-occlusion. Hemolysis, which involves the premature breakdown of red blood cells, releases free hemoglobin into circulation, contributing to oxidative stress and endothelial damage. This cascade of events heightens the inflammatory response and causes microvascular injury. Additionally, chronic hypoxia, a hallmark of SCD, results from the impaired oxygen delivery caused by the sickling of red blood cells, leading to further endothelial dysfunction and vasculopathy. This inflammatory milieu and endothelial damage in SCD predispose patients to higher susceptibility to infections, especially respiratory and urinary tract infections, which are commonly seen in individuals with HIV. [18-19].

HIV infection compounds this existing inflammatory and immune dysfunction. HIV specifically targets CD4+ T lymphocytes, which play a key role in immune defense, especially in the presence of pathogens. As the infection progresses, the depletion of CD4+ T cells weakens the immune system and impairs the body's ability to mount an effective immune response against infections. This immune deficiency leaves HIV-positive individuals with SCD more vulnerable to opportunistic infections, including those that affect the lungs, kidneys, and blood vessels. Furthermore, the presence of HIV promotes a generalized inflammatory state, which exacerbates the systemic inflammation seen in SCD. The cytokines and chemokines involved in HIV replication, such as TNF-alpha, IL-6, and IL-1, contribute to the chronic inflammation in SCD, potentially leading to more severe manifestations of both diseases. [20-22]. The interaction between HIV-induced immunosuppression and the inflammatory processes of SCD further increases the risk of serious complications such as acute chest syndrome, stroke, and renal impairment. Both conditions lead to endothelial dysfunction and can cause significant vasculopathy, which predisposes patients to ischemic events. The compounded inflammatory state accelerates the progression of organ damage, particularly in the lungs, kidneys, and liver. In the lungs, HIV-associated pulmonary complications such as pneumocystis pneumonia and tuberculosis can worsen the hypoxia and respiratory distress commonly seen in SCD patients. Similarly, renal complications, including HIV-associated nephropathy (HIVAN), can be exacerbated by the already impaired renal function in SCD. [23-25]. Therapeutically, the combination of HIV and SCD presents unique challenges. Antiretroviral therapy (ART), which is crucial for managing HIV infection, can interact with drugs used to treat SCD, such as hydroxyurea, potentially leading to adverse effects. Additionally, ART medications may cause hematologic side effects, such as neutropenia and anemia, which further complicate the hematologic management of SCD. Thus, understanding the pathophysiological mechanisms of HIV in SCD patients is essential for tailoring therapeutic approaches and mitigating potential drug interactions and side effects. [26-27].

Clinical Manifestations and Diagnosis of HIV in Sickle Cell Disease

The clinical manifestations of HIV in patients with sickle cell disease (SCD) are multifaceted and represent a complex interaction between the hematologic, immunologic, and infectious complications of both conditions. Individuals with SCD are already predisposed to a range of complications, including anemia, vaso-occlusive crises, organ damage, and chronic pain. When HIV is introduced into this already compromised clinical landscape, the resulting symptoms and complications are often more severe and difficult to manage. Both diseases contribute to a heightened inflammatory state, immunosuppression, and increased susceptibility to infections, further complicating the clinical presentation. [28-29]. HIV-positive SCD patients may present with several overlapping clinical features, making diagnosis more challenging. Symptoms of HIV infection, including fever, weight loss, fatigue, and night sweats, can overlap with those of SCD-related complications such as vaso-occlusive pain crises, chronic anemia, and organ damage. The presence of HIV can exacerbate these symptoms, causing more frequent and severe episodes of vaso-occlusion, as well as increased susceptibility to opportunistic infections such as pneumonia, urinary tract infections, and tuberculosis. Furthermore, chronic inflammation seen in both diseases may lead to progression in organ damage, particularly to the kidneys, lungs, and heart. These multi-systemic effects can result in a progressive decline in the patient's quality of life, with frequent hospitalizations, difficulty managing pain, and increased rates of morbidity and mortality [30-31].

In addition to the complications associated with the diseases themselves, HIV infection in SCD patients can also increase the risk of specific HIV-related conditions, such as HIV-associated nephropathy (HIVAN), which is characterized by progressive kidney dysfunction. HIVAN can manifest as proteinuria, edema, and an increase in serum creatinine levels, mimicking the renal manifestations of sickle cell nephropathy. Furthermore, the heightened inflammatory response caused by both HIV and SCD may contribute to the development of acute chest syndrome (ACS), a life-threatening complication of SCD that is associated with respiratory distress, hypoxia, and chest pain. In HIV-positive SCD patients, the risk of ACS is increased due to the dual effects of impaired immune function and the ongoing pulmonary complications of HIV.32-34 The diagnosis of HIV in patients with SCD can be more complex, as many clinical symptoms overlap between the two conditions. Routine screening for HIV is essential in SCD patients, particularly in regions with high prevalence of HIV. HIV testing typically involves serologic assays such as enzyme-linked immunosorbent assay (ELISA), followed by confirmatory tests like the Western blot or HIV-1 RNA PCR test. In individuals with established SCD, monitoring HIV viral load and CD4+ T cell count is necessary to assess the degree of immune suppression and to guide antiretroviral therapy (ART) initiation. SCD patients who present with worsening anemia, increased frequency of pain crises, or organ failure should be screened for HIV, particularly in areas with high HIV burden. Additionally, special attention should be given to the renal

function in HIV-positive SCD patients, as kidney involvement can often be subtle and can present with early signs of proteinuria or elevated creatinine levels.35-37

As the clinical features of HIV and SCD often overlap, a comprehensive and thorough diagnostic approach is crucial to differentiate between the two conditions and guide appropriate treatment. Imaging studies, such as chest X-rays, CT scans, and echocardiograms, may be used to assess organ involvement and rule out other causes of symptoms. For example, in suspected cases of acute chest syndrome (ACS), chest X-rays can help identify infiltrates and signs of infection, while pulmonary function tests can assess lung function. Renal function tests, including urine analysis, creatinine clearance, and kidney biopsies, are essential in diagnosing HIVAN and differentiating it from other forms of renal dysfunction in SCD.38 Moreover, close monitoring of inflammatory markers such as C-reactive protein (CRP), interleukins, and tumor necrosis factor (TNF)-alpha can help assess the degree of systemic inflammation, which is a hallmark of both HIV and SCD. This multi-pronged diagnostic approach can help physicians make timely interventions and adjust treatment plans to manage the dual burden of both conditions effectively.39

Immune Response in HIV and Sickle Cell Disease

The immune response in individuals with both HIV and sickle cell disease (SCD) is characterized by a complex interplay between immunosuppression, chronic inflammation, and dysregulated immune function. Both conditions independently lead to significant alterations in the immune system, but their coexistence in a single patient can result in exacerbated immune dysfunction, making the management of co-infected individuals particularly challenging. Understanding the immune responses in HIV and SCD is crucial for devising effective therapeutic strategies and improving patient outcomes.40 In HIV, the virus primarily targets and depletes CD4+ T cells, a central component of the adaptive immune response. As the disease progresses, the decline in CD4+ T cells leads to a weakened immune system, increasing susceptibility to opportunistic infections and impairing the body's ability to mount effective immune responses. In addition to CD4+ T cell depletion, HIV infection also induces chronic immune activation, marked by elevated levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukins (IL-6, IL-1), and interferons. This persistent inflammation contributes to the pathogenesis of several HIV-related complications, including cardiovascular disease, neurocognitive impairment, and chronic kidney disease. Moreover, the immune system's ability to distinguish between pathogenic and self-antigens is impaired in HIV-infected individuals, leading to immune dysregulation and autoimmunity.41-42

Sickle cell disease, on the other hand, is associated with a heightened state of systemic inflammation due to repeated hemolysis, vaso-occlusive crises, and endothelial damage. Hemolysis releases free hemoglobin into circulation, which acts as an endogenous danger signal and activates immune cells, including monocytes, macrophages, and neutrophils. This activation results in the release of inflammatory cytokines, promoting a vicious cycle of inflammation that worsens vascular injury and contributes to organ damage. The immune response in SCD is further complicated by defective immune function, particularly in the context of recurrent infections, as sickle cells have a reduced ability to clear pathogens due to impaired splenic function and increased sequestration of white blood cells in the microvasculature. The combination of chronic hemolysis, endothelial dysfunction, and immune system defects leads to a persistent inflammatory state, which underpins many of the clinical manifestations of SCD, such as pain crises, stroke, and organ damage.43 When HIV and SCD co-occur, the immune responses from both diseases intersect in ways that exacerbate the overall immune dysfunction. HIV-related CD4+ T cell depletion compromises the adaptive immune response, while SCD-induced chronic inflammation heightens the activation of both innate and adaptive immune cells. This synergistic effect leads to a more profound immune dysregulation and increases the risk of both infections and autoimmune disorders in co-infected patients. HIV-related immunosuppression impairs the ability of the immune system to control the inflammatory burden caused by SCD, while the chronic inflammatory state in SCD exacerbates immune dysfunction in HIV-positive individuals. As a result, co-infected patients are at a higher risk of recurrent infections, particularly in the respiratory and genitourinary tracts, as well as opportunistic infections, including pneumonia, tuberculosis, and fungal infections. Additionally, the combined immune dysfunction may increase the risk of secondary autoimmune diseases, further complicating disease management.44

The chronic inflammation in both HIV and SCD also impacts immune responses in the context of vaccinations and the body's ability to fight infections. In SCD, compromised immune function, particularly with regard to the spleen's ability to filter pathogens, leads to increased susceptibility to pneumococcal and other encapsulated bacterial infections. In HIV, the depletion of CD4+ T cells impairs the ability to generate protective antibody responses to vaccines, which can be further diminished by the concurrent inflammation in SCD. Immunization strategies for co-infected patients must be tailored to address these immune deficiencies. For example, vaccination schedules may need to be adjusted to ensure optimal immune responses, and additional doses of vaccines, such as the pneumococcal vaccine, may be necessary to provide adequate protection.45 Therapeutic interventions in HIV and SCD also have significant effects on the immune system. Antiretroviral therapy (ART), while essential for managing HIV, can alter immune function in a variety of ways. ART has been shown to increase CD4+ T cell counts and decrease viral load, restoring some degree of immune competence. However, ART may not fully reverse the immune dysfunction caused by SCD-related inflammation, and long-term ART can have additional effects on hematopoiesis and renal function. In SCD, therapies such as hydroxyurea aim to reduce the frequency of vaso-occlusive crises and inflammation by increasing fetal hemoglobin levels, which can indirectly modulate immune responses. Despite these benefits, hydroxyurea and other disease-modifying therapies may interact with ART, complicating the treatment regimens and requiring close monitoring of drug interactions and side effects.46

Management and Treatment Considerations

Managing patients with both HIV and sickle cell disease (SCD) presents unique challenges due to the complex interplay between immunosuppression from HIV and the chronic inflammation and vaso-occlusive events associated with SCD. The treatment strategy must address both conditions simultaneously, considering the distinct therapeutic approaches required for each while minimizing potential drug interactions and side effects. A multidisciplinary approach is crucial for optimizing patient outcomes, with close monitoring of both the HIV viral load and the effects of SCD-related complications, including pain crises, organ damage, and infections.47 Antiretroviral Therapy (ART) remains the cornerstone of HIV management. For individuals with HIV and SCD, ART must be selected carefully to avoid drug interactions that could exacerbate hematologic or renal complications. Some ART medications can cause bone marrow suppression, liver toxicity, or renal impairment, which may further complicate the management of SCD. Therefore, clinicians must choose ART regimens that are both effective against HIV and have minimal adverse effects on blood cells and organ function. Common first-line regimens, such as integrase strand transfer inhibitors (INSTIs) combined with nucleoside reverse transcriptase inhibitors (NRTIs), are often preferred, as they generally have a favorable side-effect profile. It is essential to monitor for potential interactions, particularly with hydroxyurea, an SCD-modifying agent, or with drugs that

affect kidney function, as both conditions often involve renal complications.48

Hydroxyurea plays a pivotal role in managing SCD by increasing fetal hemoglobin (HbF) production, which reduces sickling and improves overall disease outcomes. It has been shown to decrease the frequency of vaso-occlusive crises, acute chest syndrome, and the need for blood transfusions. For HIV-positive individuals with SCD, hydroxyurea can be particularly beneficial in reducing the inflammatory burden associated with SCD while potentially reducing the frequency of infections by improving the overall hemoglobin profile. However, there is a need for careful monitoring when hydroxyurea is used alongside ART, as certain ART medications may affect the metabolism of hydroxyurea or increase the risk of myelosuppression.45 Pain management is a central component of SCD care, especially during vaso-occlusive crises, which can be more frequent and severe in patients with both HIV and SCD due to the combined inflammatory effects of both diseases. Analgesia should be carefully managed with opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and adjunctive medications, such as anticonvulsants or antidepressants, for neuropathic pain. Opioids should be used cautiously, considering the potential for opioid resistance, drug-drug interactions, and the risk of addiction or misuse. Additionally, non-pharmacologic interventions, including physical therapy, cognitive behavioral therapy (CBT), and alternative therapies such as acupuncture, can help manage chronic pain and improve the quality of life for co-infected patients.46

Infection prevention and treatment are critical in this patient population, given the increased risk of both opportunistic infections related to HIV and infections resulting from immunocompromised states in SCD. Vaccination strategies must be optimized, with careful attention to the pneumococcal, meningococcal, and influenza vaccines, as these are particularly important in preventing infections that can exacerbate both HIV and SCD complications. Prophylactic antibiotics, such as penicillin, may be necessary in children with SCD, especially if they have functional asplenia due to repeated vaso-occlusive crises. In HIV-infected patients, prophylaxis for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PCP) or Mycobacterium tuberculosis, should be considered depending on CD4 counts and clinical status.47 Renal function is another critical consideration in the management of co-infected patients. Both HIV and SCD independently contribute to renal dysfunction. HIV-associated nephropathy (HIVAN) can lead to progressive kidney disease, while SCD can cause glomerulopathy, hematuria, and nephropathy due to the effects of sickle-shaped red blood cells on renal blood vessels. The use of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) is common in managing proteinuria and preventing kidney damage in patients with HIVAN or SCD-related kidney disease. Close monitoring of renal function is essential, and adjustments in therapy may be needed to prevent further renal impairment, particularly in the context of ART.48 Lastly, mental health support and psychosocial care are crucial for individuals with both HIV and SCD, as these conditions can lead to high levels of stress, anxiety, and depression. The burden of living with two chronic illnesses can significantly affect the psychological well-being of patients. Counseling, psychiatric support, and social services are important components of a comprehensive care plan, helping patients navigate the emotional and psychological challenges of their dual diagnoses. Interventions aimed at improving coping strategies, addressing social determinants of health, and reducing stigma related to both HIV and SCD are integral to promoting overall well-being and enhancing adherence to treatment regimens.46-48

Conclusion

Managing patients with both HIV and sickle cell disease (SCD) is a complex and multifaceted challenge that requires a holistic, patient-centered approach. The coexistence of these two chronic conditions exacerbates the pathophysiological processes, posing unique challenges in treatment and care. The intricate interplay between HIV's immunosuppressive effects and the chronic complications of SCD necessitates careful coordination across multiple specialties, ensuring that both conditions are managed effectively without compromising the patient's overall health. The integration of antiretroviral therapy (ART) with disease-modifying treatments for SCD, such as hydroxyurea, plays a pivotal role in improving disease outcomes, reducing pain crises, and minimizing the risk of organ damage. However, the management of this dual diagnosis requires constant vigilance for potential drug interactions, adverse effects, and the need for individualized care plans. Pain management, infection prevention, renal function monitoring, and psychological support are essential components that must be tailored to the unique needs of these patients.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. (2015). The interaction between sickle cell disease and HIV infection: a systematic review. *Clinical Infectious Diseases*. 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. (2019). Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. *Transfusion Medicine Reviews*; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. (2024). Sickle Cell Disease and Its Psychosocial Burdens in Africa. *InSickle Cell Disease in Sub-Saharan Africa:* 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. (2013). Sickle cell disease: new opportunities and challenges in Africa. *The scientific world journal;* 2013(1):193252.
5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. (2020). Life-threatening infectious complications in sickle cell disease: a concise narrative review. *Frontiers in Pediatrics*; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. (2024). Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology;* 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: *A Comprehensive Review.*
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. (2024). Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. (2024). Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci;* 10(1):25-36.
10. Obeagu EI, Obeagu GU. (2024). Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Asian J Dental Health Sci*; 4(1):32-37.
11. Obeagu EI, Obeagu GU. (2024). Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. (2024). Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science;* 2(2):1-17
13. Obeagu EI, Obeagu GU. (2024). Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*, 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. (2024). Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood

Transfusion Strategies. *Elite Journal of Health Science*; 2(2): 20- 35

15. Obeagu EI, Obeagu GU. (2024). Impact of Maternal Eosinophils on Neonatal Immunity in HIVExposed Infants: A Review. *Elite Journal of Immunology*; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, et all., (2023). Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport *International Journal of Biological and Applied Sciences (NIJBAS)*.
17. Ntsekhe M, Baker JV. (2023). Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. *Circulation*; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. (2024). Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, et all., (2024). Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences; 25(13):7266.
20. Obeagu EI, Obeagu GU. (2024). Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B (2024). Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*, 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, et all., (2020). de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. *BMC Infectious Diseases*; 20(1):638.
23. Bhowmik A, Banerjee P. (2015). Hematological manifestation in HIV infected children. *J Coll Physicians Surg Pak*; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. (2012). Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. *Journal of Medical Primatology*; 41(3):214-224.
25. Nouraie M, Nekhai S, Gordeuk VR. (2012). Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. *Sexually transmitted infections*; 88(7):528-533.
26. Obeagu EI, Obeagu GU. (2024). Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*; 2(1):33-45.
27. Obeagu EI, Obeagu GU. (2024). The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. (2024). Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*; 2(3): 84-99
29. Obeagu EI, Obeagu GU. (2024). Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology;* 2(3): 33-44
30. Obeagu EI, Obeagu, GU. (2024). Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*; 2(1): 42-60
31. Obeagu EI, Obeagu GU. (2024). L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine;* 2(2): 30-46
32. Obeagu EI, Obeagu GU. (2024). Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*; 2(2): 43-59
33. Obeagu EI, Obeagu GU. (2024). P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*; 2(3): 25-41
34. Obeagu EI, Obeagu GU. (2024). P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B (2024). Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. (2024). Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review;* 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. (2015). Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy.; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. (2014). Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. *BMC hematology*; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. (2024). Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. *Plos one;* 19(10): e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. (2017). Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. *Journal of blood medicine*:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, et all., (2017). Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. *PLoS One.*; 12(3): e0174233.
42. Obeagu EI, Obeagu GU. (2024). ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. *Elite Journal of Haematology;* 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. (2024). Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, et all., (2020). Hematologic alterations and early mortality in a cohort of HIV positive African patients. *PLoS One*; 15(11): e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. (2023). Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. *Journal of Blood Medicine.*:543-554.
46. Obeagu EI, Goryacheva OG. (2025). The Role of Inflammation in HIV and Sickle Cell Disease Co-Morbidity. *Lifeline HIV;* 3(1): 1-12
47. Obeagu EI, Goryacheva OG. (2025). Oxidative Stress in HIV and Sickle Cell Disease: A Double Burden. *Lifeline HIV*; 3(1): 13-24

48. Obeagu EI, Goryacheva OG. (2025). HIV and Sickle Cell Disease: A Focus on Liver Dysfunction. *Lifeline HIV*; 3(1): 25-40

DOI:10.31579/2639-4162/261